NCT03458221 - Signal TrAnsduction Pathway Activity Analysis in OVarian cancER | Biotech Hunter

Enrollment

148

Participants

Timeline

Start Date

January 31, 2023

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2026

Conditions

Recurrent Ovarian CancerSignal Transduction Pathway DeregulationTherapy-Associated Cancer

Interventions

DRUG

Letrozole Oral Product

Letrozole 2.5mg tablet - 2.5mg once dailty until progression of disease.

DRUG

Bicalutamide Oral Product

Bicalutatmide 150mg tablet - 150mg once daily until progression of disease.

DRUG

Everolimus Oral Product

Everolimus 10mg tablet - 10mg once daily until progression of disease.

DRUG

Itraconazole Oral Product

Itraconazole 100mg capsule - 300mg twice daily until progression of disease.

Trial Locations (6)

NOT_YET_RECRUITING

Radboudumc, Nijmegen

NOT_YET_RECRUITING

Erasmus MC, Rotterdam

RECRUITING

Catharina Ziekenhuis, Eindhoven

NOT_YET_RECRUITING

Amphia Hospital, Breda

NOT_YET_RECRUITING

Maastricht UMC+, Maastricht

NOT_YET_RECRUITING

Elisabeth-Tweesteden Hospital, Tilburg